Ro review 2026: the broad-menu private platform, examined

Ro is the consumer brand of a privately held telehealth company that began in 2017 as Roman, an ED-focused service for men. The company expanded into broader categories over the following years and rebranded as Ro to signal the multi-category positioning. Roman remains active as a sub-brand for men's sexual-health products; the parent platform now runs ro.co as a unified surface for all of its categories.

Ro is not publicly traded and does not file with the SEC. Quantitative claims about the company (member count, revenue, satisfaction percentages) live entirely inside Ro's own marketing — there are no audited financial statements to cross-reference, in contrast to the Hims & Hers public-company structure we cover in the parallel review. The company has raised significant venture capital and is regularly covered in trade press for funding rounds and product launches.

The product range is wide. Ro covers weight loss (branded GLP-1s as the primary line, with selective compounded products elsewhere), sexual health (branded Viagra and Cialis alongside generics and two compounded products — Ro Sparks and Daily Rise Gummies), hair regrowth for both men and women (FDA-approved finasteride and minoxidil alongside compounded combinations), premature ejaculation (Roman Swipes topical, sertraline off-label), genital herpes and cold sores (valacyclovir), fertility (hormone tests, ovulation tests, prenatal vitamins, sperm-kit service), dermatology (custom Rx skincare, LATISSE for lashes), testosterone support (supplement-based), and daily-health OTC.

The defining strategic move of recent years parallels Hims's: Ro has moved its GLP-1 line largely toward FDA-approved branded medications with manufacturer-direct partnerships, as the FDA's enforcement timeline closed in on mass-compounding (see section 06). The current GLP-1 menu — Wegovy Pill, Wegovy Pen, Zepbound, Zepbound KwikPen, Foundayo, Ozempic, Saxenda — is essentially all branded.

Two further structural notes. First, Ro says its cash prices for branded GLP-1s match TrumpRx, the White House price website, and the manufacturers' own programs (see section 02). Second, Ro is the only provider in our set with a public insurance-check tool (/weight-loss/glp1-insurance-checker/) — patients can input plan information before signing up to determine whether their insurance will cover any of the medications. This is a meaningful structural differentiator from cash-pay-only competitors.

Ro publishes its weight-loss prices on a pricing page. The bill has two parts: a membership and the medication.

Ro Body Membership is required for GLP-1 plans. The first month costs $39, refunded if Ro finds you are not eligible for a GLP-1. After that it is $74 to $149 a month depending on plan length; $74 a month is the 12-month plan, prepaid for the year.

Medication is billed on top, at cash prices that start at $149 a month for the Wegovy pill and the Foundayo pill, $199 for the Wegovy pen and $299 for the Zepbound KwikPen, and rise with the dose. Some of the lower starting prices are limited-time offers; for the Wegovy pen and Foundayo, Ro gives a sign-up deadline of 31 December 2026.

Ro states that its cash prices match LillyDirect, NovoCare and TrumpRx. TrumpRx is a White House website that lists manufacturers' cash prices for branded drugs; on 15 October 2026 it showed the same starting figures for the Wegovy pill ($149), the Wegovy pen ($199) and Zepbound ($299). The medication price at Ro is therefore the manufacturer's price; what Ro adds is the membership.

Outside weight loss — ED, hair, dermatology and fertility — product pages lead into the onboarding quiz rather than a public price list. Ro markets generic sildenafil as "up to 95% cheaper than branded". Ro Sparks and Daily Rise Gummies (compounded ED) are subscriptions priced inside the quiz.

Insurance / FSA / HSA. Ro is the only provider in our set with a dedicated insurance check tool before signup. The flow lets patients input their plan information to see whether their insurance will pay; if it does, Ro routes to insurance billing; if it doesn't, the cash-pay path applies. Ro's public pages do not state whether it accepts FSA/HSA cards or buy-now-pay-later; ask at signup.

Ro's funnel is broadly the cash-pay-telehealth template with two notable additions.

Online intake. The patient enters the onboarding quiz from any "Get started" CTA. The intake is category-specific (separate flows for weight loss, ED, hair, etc.) and dynamically expands based on answers.

Insurance check (optional, weight loss only). Before the medical intake, weight-loss patients can route through Ro's insurance-check tool to determine whether their plan will cover the prescribed medication. This is structurally unique in our set.

Provider review. A licensed provider on the Ro network reviews the intake and prescribes if appropriate. Ro does not publish quoted timelines on the homepage; per-product pages and onboarding screens may show more specific commitments.

Pharmacy fulfillment. Branded GLP-1s ship via manufacturer-direct programs (parallel to Hims's NovoCare/LillyDirect partnerships). Compounded products (Ro Sparks, Daily Rise Gummies, Ro Mane Spray, women's Hair Solution Rx, custom Rx skincare) ship via partner compounding pharmacies. Ro does not specifically name its partner pharmacies on the public surface.

Shipping. Discreet packaging, fast and free per category-page copy.

Ongoing care. Members can message providers 24/7 through the Ro app or web portal; manage goals in one place; and access a substantial library of free patient-facing tools (BMI Calculator, BMR Calculator, TDEE Calculator, Calorie Deficit Calculator, Protein Calculator, GLP-1 Insurance Checker, GLP-1 Supply Tracker).

Ro's headline weight-loss claim is "Drop 20% of your weight and keep it off." This number aligns with the outcomes documented in SURMOUNT-1 for tirzepatide at higher doses over 72 weeks — a peer-reviewed Tier A trial. For standard semaglutide, the relevant evidence remains STEP 1 with mean ~14.9% weight loss at 68 weeks. For liraglutide 3.0 mg (Saxenda — Ro carries it as a menu item), the SCALE Obesity & Prediabetes trial showed mean ~8% weight loss at 56 weeks. For Wegovy's cardiovascular benefit (referenced in Ro's marketing alongside the weight-loss claim), the SELECT trial (n=17,604, NEJM 2023) is the primary source.

A material caveat that applies across the branded menu: every one of those trials studied branded, FDA-approved semaglutide, tirzepatide, or liraglutide at defined doses. Patients on Ro's branded GLP-1 line are receiving the same FDA-approved products studied in those trials. This is materially different from the compounded-DTC providers in our set, where outcomes have to be inferred rather than directly applied.

Two compounded products that Ro highlights deserve separate evidence framing. Ro Sparks and Daily Rise Gummies are explicitly compounded ED products — not FDA-approved. The active ingredients in compounded ED products are typically the PDE5 inhibitors sildenafil and tadalafil (well-evidenced in branded trials), but the specific compounded formulations Ro dispenses are not the studied products. Ro discloses this in standard language: "Ro Sparks and Daily Rise Gummies are compounded medications. They are not FDA-approved and do not undergo FDA safety, effectiveness, or manufacturing review."

For hair regrowth: oral finasteride (Propecia, 1997) and topical minoxidil (Rogaine, 1988) are FDA-approved for hair loss. Oral minoxidil is FDA-approved only at higher doses for high blood pressure; for hair it is prescribed off-label, which Ro's own oral minoxidil page states. Ro Mane Spray and Hair Solution Rx for women are compounded with the same disclosure.

For LATISSE (lash growth): FDA-approved (Allergan, 2008).

For valacyclovir (genital herpes, cold sores): FDA-approved (multiple generic and branded sources).

For sertraline used off-label for premature ejaculation: this is a standard off-label clinical practice with meta-analytic support; the off-label nature should be foregrounded for patients.

GLP-1 therapy is a well-characterized drug class. The most common effects are gastrointestinal: nausea, reduced appetite, constipation or diarrhea — typically most noticeable during dose escalation and often easing with time. Less common but more serious risks include pancreatitis and gallbladder problems. The branded GLP-1s on Ro's menu (Wegovy, Zepbound, Foundayo, Ozempic, Saxenda, Mounjaro) carry a boxed warning based on rodent studies of thyroid C-cell tumors and are not recommended for people with a personal or family history of medullary thyroid carcinoma or MEN2. Pregnancy is a contraindication. Ro provides drug-specific Important Safety Information, which is the appropriate source for the manufacturer-authored safety language.

PDE5 inhibitors for ED — both the branded Viagra/Cialis and the generic sildenafil/tadalafil — carry standard precautions including interactions with nitrates (significant hypotension risk) and cautions in patients with severe cardiovascular disease. Ro's per-product safety information pages document these.

Because Ro primarily dispenses branded FDA-approved GLP-1s rather than compounded versions, the compounded-quality concerns relevant at compounded-DTC providers do not apply at the same scale here. (Ro Sparks, Daily Rise Gummies, Ro Mane Spray, Hair Solution Rx, custom Rx skincare remain compounded, with the corresponding caveats.)

Ro's positioning inside the FDA compounding regulatory squeeze is materially different from the compounded-DTC providers we cover. The FDA timeline — semaglutide and tirzepatide removed from shortage (Dec 2024 / Feb 2025), 503A and 503B grace periods ending in April and May 2025, the 503B Bulks List exclusion proposal of April 2026, and the public-comment deadline of 29 June 2026 (later extended to 30 July 2026; no final decision as of 7 October 2026) — applies to compounded products. Ro has moved its GLP-1 line predominantly to FDA-approved branded medications with manufacturer-direct supply.

The compounded categories where Ro retains exposure are smaller-scale: Ro Sparks and Daily Rise Gummies (ED), Ro Mane Spray (men's hair), women's Hair Solution Rx, and custom Rx skincare. These are subject to standard 503A compounding regulation, but they're not the subjects of the FDA's GLP-1-specific enforcement push.

Ro does not foreground 503A/503B specifics on the homepage. The compounded products carry the appropriate "not FDA-approved" disclosure in footer text and per-product important-safety-information pages.

For GLP-1 specifically, Ro's risk profile is closer to Hims's than to the compounded-DTC providers — both major branded operators are insulated from the immediate regulatory deadline relative to compounded competitors.

Ro's menu is broader than any single direct competitor in our set. Selected categories:

A few observations worth flagging.

Ro Sparks and Daily Rise Gummies are marketed prominently as "Best seller" and as solo-feature category cards on the homepage, despite being compounded rather than FDA-approved. The disclosure ("Ro Sparks and Daily Rise Gummies are compounded medications. They are not FDA-approved and do not undergo FDA safety, effectiveness, or manufacturing review.") sits in footer text. The visual prominence vs. the disclosure footprint is a marketing-polish observation.

LATISSE (bimatoprost) is FDA-approved for hypotrichosis of the eyelashes (approval NDA 022369, 2008). It's an unusual menu addition for a DTC men's-health platform but reflects Ro's broader multi-category positioning.

The testosterone offering is a supplement, not Rx TRT. Patients looking for FDA-approved testosterone (cypionate injection, AndroGel, KYZATREX) or compounded TRT (creams, enclomiphene) will not find them at Ro; competitors like Henry Meds, Maximus, and Hims (enclomiphene only) carry that menu.

Ro publishes a small, high-profile medical advisory team. Three senior advisors are foregrounded on the homepage; we cross-checked all three against the public NPI Registry (two on 10 June 2026, the third on 15 October 2026). All three are individually registered and active.

Ro's homepage also refers to a "former Surgeon General and Head of the DEA" among its advisers. Its advisors page names Joycelyn Elders, U.S. Surgeon General in 1993-1994, and a former deputy chief of staff to two FDA commissioners, but no former head of the DEA.

The roster is smaller than Hims's. Compared to providers in our set who publish no public roster at all (Henry, TrimRx) or who feature mid-level providers (Mochi's marketplace), Ro's advisory layer signals company-level clinical seriousness.

Reading the conflicting third-party signals. Ro presents a layered external picture. Trustpilot shows 3.9/5 across 7,674 reviews. The Better Business Bureau lists Ro as BBB-Accredited (since 22 July 2018) and rates the company A+, but its customers give a 1.1-out-of-5 review average across 335 reviews, and 738 complaints were filed in the last three years. Both are real signals; they describe different parts of the customer experience.

Pros.

Broad menu. Branded GLP-1, branded and generic ED, hair (FDA-approved and compounded), dermatology, fertility, daily-health OTC, plus LATISSE — Ro covers more single-patient use cases than any direct competitor.

No active manufacturer lawsuits. Ro pivoted to direct manufacturer partnerships (NovoCare for Wegovy/Ozempic; LillyDirect for Zepbound/Foundayo) before the compounded-DTC manufacturer-litigation wave hit competitors. Ro sells branded Zepbound through the LillyDirect channel rather than a compounded equivalent. No Eli Lilly v. Ro or Novo Nordisk v. Ro lawsuit has been filed (Ro is named in industry coverage as a Novo branded-program partner, not as a defendant).

Insurance check tool is unique in our set. Patients can determine coverage before signing up — a structural option no compounded competitor and no Hims-style branded operator offers.

Branded GLP-1 menu. Wegovy, Zepbound, Foundayo, Ozempic, Saxenda all on FDA-approved labels with manufacturer-supported supply.

Named advisers who check out. Three senior advisers are named on the homepage, and all three are active in the NPI Registry. The roster is smaller than Hims's.

BBB-Accredited (since 2018), rated A+. A meaningful baseline credential; BBB's letter grade weighs how complaints are answered, not how many there are.

Substantial patient-facing tool library — BMI Calculator, BMR Calculator, TDEE Calculator, Calorie Deficit Calculator, Protein Calculator, GLP-1 Insurance Checker, GLP-1 Supply Tracker. Real utility for the engaged patient.

Membership in industry standards bodies — Alliance for Safe Online Pharmacies (ASOP Global), American Telemedicine Association, LegitScript-certified, National Association of Boards of Pharmacy (NABP), Quest Diagnostics partnership for labs. Tier C self-disclosures, but taken together suggest a more institutionalized regulatory posture.

Cons and trade-offs.

BBB customer reviews average 1.1 out of 5, with 738 complaints in three years. Per Ro's BBB profile, 335 customer reviews average 1.1 out of 5, and 738 complaints were filed in the last three years, 393 of them in the last twelve months. The A+ grade and the complaint volume describe different things: the grade reflects how Ro responds, the volume how often customers escalate.

Trustpilot rating sits at 3.9/5. 3.9/5 across 7,674 reviews is lower than the compounded operators in our set (Mochi 4.5, Henry 4.3) and higher than Hims (2.9). The sample size relative to claimed member count (3M+ members vs. about 7,700 Trustpilot reviewers) suggests either lower review-collection effort or weaker satisfaction at scale.

The membership comes on top of the drug. The medication is billed at the manufacturer's cash price; the membership ($74 to $149 a month after a $39 first month) is added to it.

Compounded products marketed as headline "Best sellers." Ro Sparks and Daily Rise Gummies sit prominently in the sexual-health card row alongside branded Viagra and Cialis. The "not FDA-approved" disclosure is in footer text. The visual hierarchy doesn't strongly signal the difference.

Celebrity ambassador presence is unusually heavy. Serena Williams and Charles Barkley have dedicated pages (/weight-loss/serena/, /weight-loss/barkley/). The disclosure language ("Ro Ambassadors") makes the commercial nature clear, and this is a legitimate marketing strategy. But the volume of celebrity testimonials is more aggressive than competitors in the set — patients should weigh testimonials accordingly.

No public SEC transparency. Ro is privately held and does not file with the SEC. Quantitative claims (3M+ members, 95% satisfaction) live entirely inside the company's own marketing without a transparent audit path.

A former DEA head is claimed but not named. The homepage refers to a "former Surgeon General and Head of the DEA"; the advisors page names the former Surgeon General but no former DEA head.

Ro makes the most sense for the patient who wants a broad branded DTC menu with an insurance routing option and is comfortable with a private platform that doesn't offer SEC-level financial transparency. It fits people who want FDA-approved branded GLP-1 with a named advisory layer; who want to combine GLP-1, ED, hair, and dermatology under one platform; who want to check insurance coverage before committing to cash-pay; and who value a substantial patient-facing tool library.

Skip it if you weight Trustpilot signal heavily — Ro's Trustpilot score is middling, and the sample size relative to claimed member count is notably low. Skip it if you want comprehensive public pricing transparency before signup — Ro's pricing requires the onboarding quiz. Skip it if you specifically need FDA-approved testosterone (Ro doesn't carry it — Henry's KYZATREX option is closer to that need) or if you specifically want a compounded-only menu (Ro is branded-first). And approach the heavy celebrity-marketing posture with eyes open — Serena Williams and Charles Barkley are paid ambassadors, and the volume of their presence on the platform is unusual even by DTC standards.

Our editorial position is to keep head-to-head verdicts in dedicated comparison pages rather than inside any single review. The shape of Ro's position is clear enough at this level.

Against the other branded-DTC operator (Hims), Ro has a broader menu (LATISSE, fertility, women's hair, dermatology), a unique insurance-check tool, and a small named advisor roster. Hims counters with NYSE-listed transparency, a larger Trustpilot signal and a larger named advisory team. Against the compounded-DTC operators (TeleZenMD, Henry, Mochi, TrimRx), Ro is materially more expensive for GLP-1 but operates on the cleaner branded-drug evidence base. Against the multi-category compounded operators (TeleZenMD specifically), Ro's menu is broader on the branded side but narrower on the peptide/hormone side (no NAD+, no sermorelin, no PT-141, no methylene blue).

The clearest case for Ro over any of those alternatives is wanting a broad branded-DTC menu with the insurance-check option, and not being deterred by the lower Trustpilot signal.

From Ro’s public pages, read Sep 24, 2026.

Its terms name its own pharmacy and say the rest of its network are unnamed partner pharmacies; a patient may also choose their own pharmacy. The terms refer to affiliated physician practices without naming a clinician.

Read from: Ro terms of use.

How the other providers we cover answer the same question: which telehealth providers name their pharmacy.

How we reviewed this. Pricing, programs, and process details were pulled directly from Ro's public pages in June 2026 (homepage, /weight-loss/, /erectile-dysfunction/, /hair-loss/, /fertility/). Weight-loss membership and medication prices were read from Ro's /weight-loss/pricing/ page on 15 October 2026; prices in other categories sit inside the onboarding quiz.

Prescriber verification was conducted independently against the public NPI Registry for all three of Ro's foregrounded senior medical advisors — each individually registered and active, two checked on 10 June 2026 and the third on 15 October 2026.

Third-party review signals: Trustpilot shows 3.9/5 across 7,674 reviews. Clinical claims in this review are anchored to peer-reviewed primary trials (STEP 1, STEP 1 extension, SCALE, SURMOUNT-1, SURMOUNT-5, SELECT) and FDA primary sources; we do not propagate the company-stated 3M+ member count or "95% love their experience" claim as verified statistics.

Editorial independence. PeptideWellness does not accept payment from telehealth providers, compounding pharmacies, or manufacturers in exchange for coverage, placement, or scoring. We have no commercial relationship with Ro.

Editorial note: Informational only — not medical advice. FDA-approved branded medications and compounded medications carry different regulatory and clinical profiles; compounded medications are not FDA-approved. Weight loss, sexual health, hair, dermatology, and fertility decisions should be made with a licensed healthcare provider familiar with your medical history. Last reviewed June 2026.